Skip to main content

New paper (Traeger): Real-World Doxy-PEP and Bacterial STIs

paper
Published

January 15, 2025

New paper led by Michael Traeger in JAMA Internal Medicine: Doxycycline Postexposure Prophylaxis and Bacterial Sexually Transmitted Infections among Individuals Using HIV Preexposure Prophylaxis. This retrospective cohort study analyzed electronic health record data from 11,551 adults dispensed HIV preexposure prophylaxis (PrEP) at Kaiser Permanente Northern California, of whom 2,253 (19.5%) received doxycycline postexposure prophylaxis (doxyPEP). Among doxyPEP recipients, quarterly chlamydia positivity fell from 9.6% before initiation to 2.0% after (rate ratio 0.21, 95% CI 0.16 to 0.27) and syphilis positivity from 1.7% to 0.3% (rate ratio 0.20, 95% CI 0.11 to 0.37); gonorrhea declined from 10.2% to 9.0% (rate ratio 0.88, 95% CI 0.77 to 1.00). Positivity remained stable among PrEP users not dispensed doxyPEP.

Quarterly chlamydia, gonorrhea, and syphilis positivity from 24 months before to 12 months after starting doxycycline postexposure prophylaxis

PubMed · DOI